Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

  • days left to enroll
  • participants needed
  • sponsor
    Mao Jianhua
Updated on 17 August 2021


This open-labeled, one-center study is designed to evaluate the efficacy and safety of roxadustat in ESA-nave and ESA-treated pediatric patients with CKD Stages 3, 4, and 5 who are receiving dialysis or not. The study will enroll patients between the ages of 2 to <18 years. Approximately 30 patients will be enrolled.


This study is to evaluate the use of roxadustat for renal anemia in pediatric patients with CKD

Condition Anemia Associated With Chronic Kidney Disease
Treatment Roxadustat
Clinical Study IdentifierNCT04925011
SponsorMao Jianhua
Last Modified on17 August 2021


Yes No Not Sure

Inclusion Criteria

Estimated glomerular filtration rate (Bedside Schwartz formula) of < 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for dialysis or non-dialysis patients
For ESA-nave patients, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be < 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be 9.0 g/dL and 12.5 g/dL
Ferritin >50 ng/mL and transferrin saturation >10%

Exclusion Criteria

Uncontrolled hypertension as judged by the principal investigator prior to screening
Known hematologic disease related anemia (including PRCA)
Known malignancy within the past 5 years before screening
History of severe anaphylaxis or known allergic to ingredient of roxadusta
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3x upper limit of normal (ULN) and total bilirubin (Tbili) 2x ULN(obtained from screening visit)
Serum folate and vitamin B12 > LLN and cannot be corrected (obtained from screening visit)
Any RBC transfusion during the past 4 weeks before screening
Any prior exposure to roxadustat or any other HIF-PH inhibitor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note